Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Celsion Corp (CLSN)

Celsion Corp (CLSN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,031
  • Shares Outstanding, K 7,099
  • Annual Sales, $ 500 K
  • Annual Income, $ -20,770 K
  • 60-Month Beta 2.31
  • Price/Sales 36.06
  • Price/Cash Flow N/A
  • Price/Book 0.32
Trade CLSN with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 64.43%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,348.30% on 02/15/22
  • IV Low 0.00% on 08/08/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 9
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 395
  • Open Int (30-Day) 550

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -1.12
  • Number of Estimates 4
  • High Estimate -0.77
  • Low Estimate -1.76
  • Prior Year -0.90
  • Growth Rate Est. (year over year) -24.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.95 +32.13%
on 07/18/22
2.69 -4.46%
on 08/05/22
+0.43 (+20.09%)
since 07/08/22
3-Month
1.80 +42.78%
on 06/17/22
3.16 -18.67%
on 05/09/22
-0.57 (-18.15%)
since 05/06/22
52-Week
1.80 +42.78%
on 06/17/22
17.70 -85.48%
on 08/09/21
-13.78 (-84.28%)
since 08/06/21

Most Recent Stories

More News
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022

LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based...

CLSN : 2.57 (+1.18%)
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy...

CLSN : 2.57 (+1.18%)
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit Full Enrollment Expected by Third Quarter of 2022 ...

CLSN : 2.57 (+1.18%)
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past...

BIOV.CN : 0.115 (-11.54%)
BVAXF : 0.0980 (-10.91%)
CLSN : 2.57 (+1.18%)
IMGN : 5.39 (-1.10%)
ZNTL : 30.77 (+0.16%)
BMY : 73.80 (+2.33%)
Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates

PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies Phase II study of GEN-1 in ovarian cancer 85% enrolled with full enrollment...

CLSN : 2.57 (+1.18%)
Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022

LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based...

CLSN : 2.57 (+1.18%)
Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows Neutralizing Activity Against 2 Strains of the COVID-19 Virus The Goal to Provide...

CLSN : 2.57 (+1.18%)
Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting

 Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR Annual Meeting LAWRENCEVILLE,...

CLSN : 2.57 (+1.18%)
Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress

LAWRENCEVILLE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy...

CLSN : 2.57 (+1.18%)
Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

LAWRENCEVILLE, NJ, April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its...

CLSN : 2.57 (+1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the...

See More

Key Turning Points

3rd Resistance Point 2.80
2nd Resistance Point 2.72
1st Resistance Point 2.65
Last Price 2.57
1st Support Level 2.50
2nd Support Level 2.42
3rd Support Level 2.35

See More

52-Week High 17.70
Fibonacci 61.8% 11.63
Fibonacci 50% 9.75
Fibonacci 38.2% 7.87
Last Price 2.57
52-Week Low 1.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar